Welcome to our dedicated page for Argenx Se news (Ticker: ARGX), a resource for investors and traders seeking the latest updates and insights on Argenx Se stock.
argenx SE reports developments as a global immunology company developing and commercializing antibody-based medicines for severe autoimmune diseases. Its updates center on VYVGART (efgartigimod alfa-fcab) and VYVGART Hytrulo (efgartigimod alfa and hyaluronidase-qvfc), including approved use in adult generalized myasthenia gravis and clinical and regulatory work across myasthenia gravis and chronic inflammatory demyelinating polyneuropathy.
Recurring announcements also cover product sales, business updates, presentations of neuromuscular data, and pipeline progress for candidates such as empasiprubart, a monoclonal antibody targeting complement factor C2, and adimanebart. Governance items include annual general meeting results, board appointments, and leadership transitions for the Euronext- and Nasdaq-listed foreign issuer.
On September 2, 2020, argenx (Euronext & Nasdaq: ARGX) announced participation in key healthcare conferences. Management will conduct a fireside chat at the Baird Global Healthcare Conference on September 9 at 12:15 p.m. ET, followed by the Morgan Stanley Global Healthcare Conference on September 14 at 1:30 p.m. ET and BofA Global Healthcare Conference on September 17 at 10:50 a.m. BST. Lastly, a panel will take place at the Stifel Immunology & Inflammation Summit on October 1 at 11:00 a.m. ET. More details are available on the company’s website.